Kathleen Dooling

6.4k citations

66 papers · 3.6k indexed · 4 hit papers · h-index 26

Impact in

Health top 0.5%
- Vaccine Coverage and Hesitancy
Modeling and Simulation top 0.5%
- COVID-19 epidemiological studies

Papers in

Health 18
- Vaccine Coverage and Hesitancy 18
Parasitology 12
- Bartonella species infections research 10
- Vector-borne infectious diseases 5

Co-authors: Grace M. Lee Rafael Harpaz Sara E. Oliver Angela Guo H. Keipp Talbot Beth P. Bell Megan Wallace José R. Romero
Journals: MMWR Morbidity and Mortality Weekly Report (16 papers)Vaccine (6 papers)Open Forum Infectious Diseases (6 papers)Clinical Infectious Diseases (4 papers)The Journal of Infectious Diseases (4 papers)
Partner nations: United States Canada Egypt

In The Last Decade

Kathleen Dooling

64 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 2022 · 133 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 MMWR Morbidity and Mortality Weekly Report
2021 PubMed
2020 MMWR Morbidity and Mortality Weekly Report
2018 MMWR Morbidity and Mortality Weekly Report

Peers

Countries citing papers authored by Kathleen Dooling

Since Specialization

Citations

This map shows the geographic impact of Kathleen Dooling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Dooling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Dooling more than expected).

Fields of papers citing papers by Kathleen Dooling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Dooling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Dooling. The network helps show where Kathleen Dooling may publish in the future.

Co-authors

The 25 scholars most cited alongside Kathleen Dooling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kathleen Dooling Line = papers co-authored together Kathleen Dooling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021 Journal of Opioid Management ·Kathleen Dooling, Jessica Leung, Michele K. Bohm	2024	0
2	A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States Vaccine ·Megan Wallace, Hannah G. Rosenblum, Danielle Moulia, Karen R. Broder, Tom T. Shimabukuro, Christopher A. Taylor, Fiona P. Havers, Sarah Meyer, Kathleen Dooling, Sara E. Oliver, Stephen C. Hadler, Julia W. Gargano	2023	11
3	Modeling the Impact of Vaccination Strategies for Nursing Homes in the Context of Increased Severe Acute Respiratory Syndrome Coronavirus 2 Community Transmission and Variants Clinical Infectious Diseases ·Inga Holmdahl, Rebecca Kahn, Kara Jacobs Slifka, Kathleen Dooling, Rachel B. Slayton	2022	10
4	Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies PLoS ONE ·Megan Wallace, Jennifer P. Collins, Heidi L. Moline, Ian D. Plumb, Monica Godfrey, Rebecca L. Morgan, Doug Campos‐Outcalt, Sara E. Oliver, Kathleen Dooling, Julia W. Gargano	2022	6
5	Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years Value in Health ·Andrew J. Leidner, Tara C. Anderson, Neti Eka Jayanti, Ismael R. Ortega‐Sanchez, Angela Guo, Jamison Pike, Lisa A. Prosser, Kathleen Dooling	2022	4
6	Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine Journal of General Internal Medicine ·Laura P. Hurley, Sean T. O’Leary, Kathleen Dooling, Tara C. Anderson, Lori A. Crane, Jessica R. Cataldi, Michaela Brtnikova, Brenda L. Beaty, А.А. Калмыков, Angela Guo, Megan C. Lindley, Allison Kempe	2022	12
7	Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States Vaccine ·Jessica Leung, Elizabeth B. Gray, Tara C. Anderson, Levent Sarıyıldız, Kathleen Dooling	2022	4
8	Modeling strategies for the allocation of SARS-CoV-2 vaccines in the United States Vaccine ·U. Metser, Prabasaj Paul, Kathleen Dooling, Sara E. Oliver, Pragati Prasad, Molly Steele, Paul A. Gastañaduy, Michael A. Johansson, Matthew Biggerstaff, Rachel B. Slayton	2022	12
9	Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018 Human Vaccines & Immunotherapeutics ·Tara C. Anderson, Jessica Leung, Rafael Harpaz, Kathleen Dooling	2021	10
10	Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure Clinical Infectious Diseases ·Héctor S. Izurieta, V.S. Korko, Richard A. Forshee, Yun Lu, Jin Ming-hong, Fan Bai, Yoganand Chillarige, Ruth Link‐Gelles, 罗光太, Michael Wernecke, Thomas MaCurdy, Jeffrey A. Kelman, Kathleen Dooling	2021	74
11	Shingles Vaccination of U.S. Adults Aged 50–59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine American Journal of Preventive Medicine ·Peng-Jun Lu, Mei-Chuan Hung, Anup Srivastav, Walter W. Williams, Kathleen Dooling	2020	14
12	The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 MMWR Morbidity and Mortality Weekly Report ·Kathleen Dooling, Mona Marin, Megan Wallace, Nancy McClung, Mary E. Chamberland, Grace M. Lee, H. Keipp Talbot, José R. Romero, Beth P. Bell, Sara E. Oliver	2020	278
13	The Advisory Committee on Immunization Practices’ Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine—United States, 2020 American Journal of Transplantation ·Nancy McClung, Mary E. Chamberland, Kathy Kinlaw, RJ Van Enk, Megan Wallace, Beth P. Bell, Grace M. Lee, H. Keipp Talbot, José R. Romero, Sara E. Oliver, Kathleen Dooling	2020	19
14	Ten years of experience with herpes zoster vaccine in primary care- how attitudes and practices have changed and what it may mean for a new zoster vaccine Vaccine ·Angela Guo, Megan C. Lindley, Laura P. Hurley, Patrícia Alcântara Vianna, Mandy A. Allison, Sean T. O’Leary, Lori A. Crane, Michaela Brtnikova, Brenda L. Beaty, Allison Kempe, Kathleen Dooling	2019	6
15	Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018 MMWR Morbidity and Mortality Weekly Report ·Elisabeth M. Hesse, Tom T. Shimabukuro, John R. Su, Beth F. Hibbs, Kathleen Dooling, D Allaire, Paige Lewis, Carmen S. Ng, Maria Cano	2019	48
16	Cost-effectiveness of adult vaccinations: A systematic review Vaccine ·Andrew J. Leidner, Neil Murthy, Harrell W. Chesson, Matthew Biggerstaff, Charles Stoecker, Aaron M. Harris, Anna M. Acosta, Kathleen Dooling, Carolyn B. Bridges	2018	87
17	Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines American Journal of Transplantation ·Kathleen Dooling, Angela Guo, Manisha Patel, Grace M. Lee, Kelly L. Moore, Edward A. Belongia, Rafael Harpaz	2018	43
18	Primary care physicians’ experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV) Vaccine ·Laura P. Hurley, Mandy A. Allison, Kathleen Dooling, Sean T. O’Leary, Lori A. Crane, Michaela Brtnikova, Brenda L. Beaty, Patrícia Alcântara Vianna, Angela Guo, Megan C. Lindley, Allison Kempe	2018	23
19	Nutritional Status of Under-five Children Living in an Informal Urban Settlement in Nairobi, Kenya Journal of Health Population and Nutrition ·Beatrice Olack, Heather Burke, Leonard Cosmas, Sapna Bamrah, Kathleen Dooling, Daniel R. Feikin, Leisel Talley, Robert F. Breiman	2011	148
20	Vancouver's supervised injection facility challenges Canada's drug laws Canadian Medical Association Journal ·Kathleen Dooling, Liyuan Deng	2010	24

About Kathleen Dooling

Kathleen Dooling is a scholar working on Health, Parasitology, Virology, Epidemiology and Dermatology, having authored 66 papers that have together received 3.6k indexed citations. Recurring topics across this work include Herpesvirus Infections and Treatments (28 papers), Vaccine Coverage and Hesitancy (18 papers), SARS-CoV-2 and COVID-19 Research (17 papers), Bartonella species infections research (10 papers), Acne and Rosacea Treatments and Effects (8 papers), Hepatitis Viruses Studies and Epidemiology (5 papers), Vector-borne infectious diseases (5 papers) and Rabies epidemiology and control (5 papers). The work is most often cited by research in Health (1.1k citations), Modeling and Simulation (382 citations), Infectious Diseases (1.4k citations), Parasitology (319 citations) and Epidemiology (1.5k citations). Kathleen Dooling has collaborated with scholars based in United States, Canada and Egypt. Frequent co-authors include Grace M. Lee, Rafael Harpaz, Sara E. Oliver, Angela Guo, H. Keipp Talbot, Beth P. Bell, Megan Wallace, José R. Romero, Nancy McClung and Mary E. Chamberland. Their work appears in journals such as MMWR Morbidity and Mortality Weekly Report, Vaccine, Open Forum Infectious Diseases, Clinical Infectious Diseases and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact